December 8th, 2004. In response to an editorial that appeared today on the New England Journal of Medicine website, Merck & Co., Inc. believes that it is important to emphasize that the company promptly and appropriately disclosed the results of the VIGOR (VIOXX Gastrointestinal Outcomes Research) study. Merck correctly communicated about the benefits ... [More >>]
September 30th, 2004. Results of a recent study on Vioxx confirmed long-standing concerns that the drug increases the risk of stroke and heart attack, spurring maker Merck to voluntarily pull the drug worldwide (in some countries, the drug is marketed under the name "Ceoxx"). Vioxx is regularly prescribed for treatment of arthritis and acute ... [More >>]
September 30th, 2004. (Press Release) The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients of this action and to advise them to consult with ... [More >>]
September 30th, 2004. Merck & Co., Inc. today announced a voluntary worldwide withdrawal of VIOXX® (rofecoxib), its arthritis and acute pain medication. The company's decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial. The trial, which ... [More >>]
February 3rd, 2004. From the Pittsburgh Post Gazette: A jury has awarded $6 million to a Shaler couple for injuries the husband received after repeated exposure to asbestos. The Common Pleas Court jury ordered DeZurik Inc. of Sartell, Minn., to pay the money to William and Lois Lisac. ... [More >>]
December 30th, 2003. About Ephedra Ephedra is an adrenaline-like stimulant derived from botanicals that can have potentially dangerous effects on the heart. Ephedra's Adverse Side Effects ... [More >>]
December 30th, 2003. (Press Release) HHS Secretary Tommy G. Thompson today announced that the Food and Drug Administration (FDA) has issued a consumer alert on the safety of dietary supplements containing ephedra and has notified manufacturers of its intent to publish a final rule on dietary supplements containing ephedrine alkaloids. The rule will state that ... [More >>]
May 22nd, 2001. In response to news and analyst reports of data the Company first released a year ago, Merck & Co., Inc. today reconfirmed the favorable cardiovascular safety profile of Vioxx(R) (rofecoxib), its medicine that selectively inhibits COX-2. Vioxx was approved by the Food and Drug Administration in May 1999 for the ... [More >>]
Goldberg, Persky & White, P.C. | 1030 Fifth Ave | Pittsburgh, PA 15219
800-471-3980 | Fax: 412-471-8308 | Email
Greensburg, PA | Johnstown, PA | Weirton, WV | Saginaw, MI | Allen Park, MI
Personal Injury Lawyers [ mesothelioma | nursing home abuse | medical malpractice]
Last Updated: September 17, 2008. 05:12:04 pm
Copyright 2008 Goldberg, Persky & White, P.C. The information provided by or linked to from this web site is intended to educate and inform victims of asbestos-related disease and other occupational injuries. The Goldberg, Persky & White, P.C. web site is intended for informational purposes only and is not to be construed as medical or legal advice. Visitors who are in need of legal or medical advice should consult with a professional licensed in their state of residence. The opinions expressed herein by persons or organizations other than Goldberg, Persky & White, P.C. are not necessarily endorsed by Goldberg, Persky & White, P.C. No attorney-client relationship is established by visiting our website or sending us Email. Copyright (c) 2008, Goldberg, Persky & White, P.C. All Rights Reserved.
